Drug Approval | December 28, 2024
Shilpa Medicare's Unit IV receives Eurasia GMP approval
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
This approval is a significant achievement in expanding the availability of this critical therapeutic,
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
SPARC to receive 55% equity in Tiller Therapeutics
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Subscribe To Our Newsletter & Stay Updated
